Catabasis

Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
CP Wire
Tue, 09/25/18 - 11:41 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals Initiates Ph III Trial for Promising Duchenne Muscular Dystrophy Drug
Tue, 09/25/18 - 10:12 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Mon, 07/9/18 - 09:07 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
CP Wire
Thu, 04/26/18 - 09:49 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
Wed, 04/25/18 - 07:40 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
CP Wire
Wed, 04/18/18 - 09:43 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
restructuring
layoffs
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
Tue, 04/17/18 - 06:50 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Prescribed Reading: DMD, MS and other acronyms
Biopharma Dive
Sun, 10/8/17 - 11:22 am
Celgene
Nimbus
Endocyte
Amicus Therapeutics
Catabasis
Motif Biosciences
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
Mon, 02/27/17 - 09:15 am
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Top 6 Biopharma Gainers of the Past Week
24/7 Wall St
Tue, 10/4/16 - 10:20 am
Catabasis
Sarepta Therapeutics
Anavex
Biogen
Array Biopharma
GW Pharma
Catabasis shares fall 50% as cholesterol drug misses study goal
Marketwatch
Wed, 06/8/16 - 10:33 am
Catabasis
clinical trials
CAT-2054
Duchenne drug by Cambridge's Catabasis looks safe in early trial
Bizjournals.com
Mon, 01/25/16 - 09:48 am
Duchenne Muscular Dystrophy
Catabasis
Biotechs line up for a busy week of IPOs
Fierce Biotech
Mon, 06/22/15 - 11:17 am
biotech
IPOs
Seres Therapeutics
Glaukos
Pieris
Catabasis